Pentixapharm Secures FDA IND Clearance for Phase 3 PANDA Study

Pentixapharm Holding AG, a Berlin-based biotech firm, has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This clearance allows the start of the company's Phase 3 PANDA study for a cardiovascular diagnostic program targeting treatment-resistant hypertension associated with Primary Aldosteronism.

The study aims to evaluate a novel imaging method intended to improve patient stratification, addressing significant gaps in cardiovascular and endocrine disease diagnostics. This development follows strategic consultations with the FDA, ensuring alignment on study design and regulatory pathways.

Pentixapharm's CXCR4-targeted platform proposes an innovative approach to diagnosing cardiovascular conditions, potentially leading to better treatment guidance by more accurately subtype differentiation. The company is set to pursue a rapid study initiation while engaging with prospective strategic partners and seeking financial support for further U.S. market expansion.